Samil Pharmaceutical Co.,Ltd (KRX:000520)
9,590.00
-30.00 (-0.31%)
Apr 24, 2026, 3:30 PM KST
KRX:000520 Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 6,412 | 5,137 | 906.14 | 1,903 | 3,992 |
Short-Term Investments | - | - | - | - | 11,269 |
Cash & Short-Term Investments | 6,412 | 5,137 | 906.14 | 1,903 | 15,261 |
Cash Growth | 24.82% | 466.91% | -52.40% | -87.53% | -11.26% |
Accounts Receivable | 35,417 | 35,025 | 35,813 | 34,181 | 31,012 |
Other Receivables | 247.87 | 754.71 | 86.62 | 123.85 | 120.23 |
Receivables | 35,665 | 35,779 | 35,900 | 34,304 | 31,133 |
Inventory | 34,833 | 34,770 | 32,511 | 24,742 | 24,177 |
Prepaid Expenses | 1,849 | 12,189 | 11,159 | - | - |
Other Current Assets | 3,199 | 3,469 | 638.27 | 13,832 | 6,140 |
Total Current Assets | 81,958 | 91,346 | 81,115 | 74,781 | 76,711 |
Property, Plant & Equipment | 242,715 | 252,893 | 242,198 | 233,946 | 103,394 |
Long-Term Investments | 819.59 | 719.88 | 797.39 | 782.42 | 838.64 |
Other Intangible Assets | 3,727 | 4,708 | 1,917 | 3,136 | 1,295 |
Long-Term Accounts Receivable | -0 | 1,033 | 0 | 0 | 0 |
Long-Term Deferred Charges | 1,755 | 804.2 | 902.04 | - | - |
Other Long-Term Assets | 40,627 | 43,567 | 43,750 | 44,054 | 44,167 |
Total Assets | 371,602 | 395,071 | 370,680 | 356,700 | 226,405 |
Accounts Payable | 19,178 | 19,159 | 21,004 | 13,660 | 8,541 |
Accrued Expenses | 5,281 | 4,054 | 3,282 | 4,013 | 11,153 |
Short-Term Debt | 65,846 | 54,184 | 74,868 | 80,562 | 75,733 |
Current Portion of Long-Term Debt | 74,610 | 9,164 | 49,830 | 4,940 | 16,560 |
Current Portion of Leases | 731.38 | 685.6 | 387.37 | 452.59 | 308.27 |
Current Income Taxes Payable | 386.87 | 1,646 | 2,417 | 1,949 | - |
Current Unearned Revenue | 97.29 | 123.72 | 112.34 | 179.99 | 171.28 |
Other Current Liabilities | 19,031 | 17,645 | 16,774 | 26,836 | 9,208 |
Total Current Liabilities | 185,163 | 106,660 | 168,675 | 132,592 | 121,674 |
Long-Term Debt | 21,614 | 84,390 | 49,568 | 71,918 | 31,911 |
Long-Term Leases | 1,222 | 1,659 | 1,225 | 1,387 | 1,003 |
Long-Term Unearned Revenue | 1,888 | 6.27 | 36.38 | 66.15 | 222.65 |
Pension & Post-Retirement Benefits | 21,921 | 16,991 | 11,310 | 6,626 | 1,646 |
Long-Term Deferred Tax Liabilities | 4,661 | 7,493 | 9,752 | 13,172 | - |
Other Long-Term Liabilities | 1,870 | 1,748 | 2,286 | 5,120 | 4,202 |
Total Liabilities | 238,340 | 218,947 | 242,853 | 230,881 | 160,658 |
Common Stock | 10,846 | 10,846 | 7,613 | 6,857 | 6,769 |
Additional Paid-In Capital | 86,437 | 86,145 | 44,008 | 40,481 | 35,248 |
Retained Earnings | -16,279 | 19,937 | 28,019 | 26,605 | 27,741 |
Treasury Stock | -2,517 | -2,517 | -4,161 | -4,142 | -5,431 |
Comprehensive Income & Other | 54,776 | 61,713 | 52,349 | 56,019 | 1,420 |
Shareholders' Equity | 133,262 | 176,124 | 127,827 | 125,820 | 65,746 |
Total Liabilities & Equity | 371,602 | 395,071 | 370,680 | 356,700 | 226,405 |
Total Debt | 164,023 | 150,081 | 175,879 | 159,258 | 125,515 |
Net Cash (Debt) | -157,611 | -144,944 | -174,973 | -157,355 | -110,254 |
Net Cash Per Share | -7424.11 | -8059.84 | -12095.82 | -11286.13 | -7972.68 |
Filing Date Shares Outstanding | 21.23 | 21.23 | 14.46 | 14.25 | 13.77 |
Total Common Shares Outstanding | 21.23 | 21.23 | 14.46 | 14.25 | 13.77 |
Working Capital | -103,204 | -15,314 | -87,560 | -57,811 | -44,964 |
Book Value Per Share | 6277.17 | 8296.13 | 8838.31 | 8830.45 | 4776.06 |
Tangible Book Value | 129,535 | 171,416 | 125,911 | 122,683 | 64,451 |
Tangible Book Value Per Share | 6101.63 | 8074.38 | 8705.79 | 8610.32 | 4681.97 |
Land | 64,487 | 64,487 | 64,487 | 67,149 | 2,501 |
Buildings | 146,477 | 149,900 | 47,136 | 47,154 | 46,000 |
Machinery | 87,789 | 87,698 | 44,846 | 43,178 | 44,758 |
Construction In Progress | 1,910 | 41.7 | 132,199 | 120,009 | 55,341 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.